Multi-Country Prospective ObserVAtionaL, Cohort Study of Patients With Moderate to Severe Chronic PlaqUE Psoriasis (VALUE)
Latest Information Update: 20 Nov 2025
At a glance
- Drugs Risankizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms VALUE
- Sponsors AbbVie
Most Recent Events
- 17 Nov 2025 Status changed from active, no longer recruiting to completed.
- 18 Jun 2024 Planned End Date changed from 30 Aug 2025 to 30 Jul 2025.
- 18 Jun 2024 Planned primary completion date changed from 30 Aug 2025 to 30 Jul 2025.